Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

MAbs. Jan-Dec 2020;12(1):1854149. doi: 10.1080/19420862.2020.1854149.

Abstract

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.

Keywords: BGB-DXP593; COVID-19; CT-P59; GSK4182136; LY-CoV016; LY-CoV555; REGN-COV2; SARS-CoV-2; VIR-7831; bamlanivimab; monoclonal antibody.

MeSH terms

  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / metabolism*
  • Antibodies, Neutralizing / genetics
  • Antibodies, Neutralizing / metabolism*
  • Antibodies, Viral / genetics
  • Antibodies, Viral / metabolism*
  • COVID-19 / immunology*
  • COVID-19 / therapy*
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Immunization, Passive / methods
  • SARS-CoV-2 / physiology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral

Supplementary concepts

  • COVID-19 serotherapy